H Hawle
Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08)
Ruhstaller T, Mingrone W, Montemurro M, Girschikofsky M, Schmidt S, Bitzer M, Bedenne L, Brauchli P, Stahl M, Hess V, Mariette C, Hawle H, Thuss-Patience P, Hayoz S, Schacher S, Knorrenschild J, Schnider A, Plasswilm L, Budach W, Eisterer W, Swiss Group for Clinical Cancer Research (SAKK), the German Esophageal Cancer Study Group, the Austrian ‘Arbeitsgemeinschaft Medikamentöse Tumortherapie’ (AGMT), and the Fédération Francophone de Cancérologie Digestive (FFCD)/Fédération de Recherche en Ch. Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08). Ann Oncol 2018; 29:1386-1393.
01.06.2018Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08)
01.06.2018Ann Oncol 2018; 29:1386-1393
Ruhstaller Thomas, Mingrone W, Montemurro M, Girschikofsky M, Schmidt S C, Bitzer M, Bedenne L, Brauchli P, Stahl M, Hess V, Mariette C, Hawle H, Thuss-Patience P, Hayoz S, Schacher S, Knorrenschild J R, Schnider A, Plasswilm L, Budach W, Eisterer W, Swiss Group for Clinical Cancer Research (SAKK), the German Esophageal Cancer Study Group, the Austrian ‘Arbeitsgemeinschaft Medikamentöse Tumortherapie’ (AGMT), and the Fédération Francophone de Cancérologie Digestive (FFCD)/Fédération de Recherche en Ch
Low-Dose Fulvestrant Maintained Long-Term Complete Remission after Poor Response to Previous Endocrine Therapies in a Patient with Advanced Breast Cancer
Hawle H, Hess D, Mueller A, Thürlimann B. Low-Dose Fulvestrant Maintained Long-Term Complete Remission after Poor Response to Previous Endocrine Therapies in a Patient with Advanced Breast Cancer. Case Rep Oncol 2010; 3:131-136.
29.04.2010Low-Dose Fulvestrant Maintained Long-Term Complete Remission after Poor Response to Previous Endocrine Therapies in a Patient with Advanced Breast Cancer
29.04.2010Case Rep Oncol 2010; 3:131-136
Hawle H, Hess Dagmar, Mueller A, Thürlimann Beat
Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial
Rabaglio M, Coates A, Goldhirsch A, Gelber R, Smith I, Láng I, Nogaret J, Pienkowski T, Colleoni M, Paridaens R, Forbes J, Campone M, Mouridsen H, Thürlimann B, Hawle H, Castiglione-Gertsch M, Price K, Sun Z, BIG 1-98 Collaborative and International Breast Cancer Study Groups. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Ann Oncol 2009; 20:1489-98.
01.09.2009Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial
01.09.2009Ann Oncol 2009; 20:1489-98
Rabaglio M, Coates A S, Goldhirsch A, Gelber R D, Smith I, Láng I, Nogaret J-M, Pienkowski T, Colleoni M, Paridaens R J, Forbes J F, Campone M, Mouridsen H, Thürlimann Beat, Hawle H, Castiglione-Gertsch M, Price K N, Sun Z, BIG 1-98 Collaborative and International Breast Cancer Study Groups
Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00)
Perey L, Goldhirsch A, Köberle D, Clément P, Dietrich D, Fiche M, Wildiers H, Nolé F, Zaman K, Hawle H, Paridaens R, Thürlimann B. Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00). Ann Oncol 2007; 18:64-9.
01.01.2007Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00)
01.01.2007Ann Oncol 2007; 18:64-9
Perey L, Goldhirsch A, Köberle Dieter, Clément P, Dietrich D, Fiche M, Wildiers H, Nolé F, Zaman K, Hawle H, Paridaens R, Thürlimann Beat